Study of High Density Lipoprotein Function in Type 1 Diabetic Patients With Nephropathy

Inclusion criteria

Inclusion criteria

GROUP C (CONTROLS) :

• age > 18 years
• a person who has given oral consent
• Non-diabetics
• Fasting plasma glucose < 6.10 mmol/L (1.1 g/L)
• Triglyceridemia < 1.7 mmol/L (1.5 g/l)
• HDL-C concentration > 1.30 mmol/L (for women and 1.03 mmol/L for men)
• Glomerular filtration flow rate > 90 mL/min/1.73m2 (These thresholds correspond to the standard thresholds for these parameters)

Inclusion criteria

GROUP T1D-N (WITH NORMAL ALBUMINURIA) :

• age > 18 years
• a person who has given oral consent
• Diabetic type 1 (based on the patient's clinical history and/or the presence of anti-glutamate decarboxylase autoantibodies and/or plasma C-peptide less than 0.5 ng/l)
• HbA1c between 6 and 9%.
• normal albuminuria (albumin/creatinine ratio < 2.5 mg/mmol in men and < 3.5 in women)
• glomerular filtration rate > 90 mL/min/1.73m2

Inclusion criteria

GROUP T1D-MICRO (WITH MICROALBUMINURIA)

• age > 18 years
• a person who has given oral consent
• Diabetic type 1 (based on the patient's clinical history and/or the presence of anti-glutamate decarboxylase autoantibodies and/or plasma C-peptide less than 0.5 ng/l)
• HbA1c between 6 and 9%.
• Microalbuminuria (albumin/creatinine ratio > 2.5 mg/mmol in men and > 3.5 in women, and < 30 mg/mmol)
• glomerular filtration rate > 90 mL/min/1.73m2

Inclusion criteria

GROUP T1D-MACRO (WITH MACROALBUMINURIA)

• age > 18 years
• a person who has given oral consent
• Diabetic type 1 (based on the patient's clinical history and/or the presence of anti-glutamate decarboxylase autoantibodies and/or plasma C-peptide less than 0.5 ng/l)
• HbA1c between 6 and 9%.
• Macroalbuminuria (albumin/creatinine ratio > 30 mg/mmol)
• glomerular filtration rate > 45 mL/min/1.73m2

Exclusion criteria

• Protected adult
• Patient not affiliated to a social security scheme
• Pregnant or breastfeeding woman
• Drugs interfering with lipid metabolism outside insulin for DT1 : hypolipidemic (only for patients included in the DT1-micro group), corticosteroid, estroprogestogens, retinoic acid, antiproteases.
• BMI > 30 kg/m2